Burzynski Publishes More Results With Brain Stem Gliomas

[Guest guest]

S

Wed, 05 Apr 2006 19:21:08 -0000

[burzynskiSupport] Burzynski Publishes More Results With

Brain Stem Gliomas

 

 

(Mod. note: Burzynski is treating these cancers with nontoxic amino

acid parts )

 

 

 

 

Burzynski Continues to Show Efficacy with Antineoplaston Therapy in

Latest Publication

 

http://www.medscape.com/medline/abstract/16484713?queryText=

antineoplastons

 

Targeted therapy with antineoplastons A10 and AS2-1 of high-grade,

recurrent, and progressive brainstem glioma.

Medscape Newsletters

 

Integr Cancer Ther. 2006; 5(1):40-7 (ISSN: 1534-7354)

Burzynski SR; Janicki TJ; Weaver RA; Burzynski B

Department of Internal Medicine, Burzynski Clinic, Houston, Texas 77055,

USA. srb

 

 

BACKGROUND: Brainstem glioma carries the worst prognosis of all

malignancies of the brain. Most patients with brainstem glioma fail

standard radiation therapy and chemotherapy and do not survive longer

than 2 years.

 

Treatment is even more challenging when an inoperable tumor is of

high-grade pathology (HBSG). The objective of this report is to

summarize the outcome of patients with HBSG treated with

antineoplastons in 4 phase 2 trials. Patients: The following group of

18 patients was evaluable: 4 patients with glioblastomas and 14

patients with anaplastic HBSG. Fourteen patients

had diffuse intrinsic tumors. Twelve patients suffered from

recurrence, and 6 patients did not have radiation therapy or

chemotherapy.

 

METHODS:

Antineoplastons, which consist of antineoplaston A10 (A10I) and AS2-1

injections, were given in escalating doses by intravenous injections.

The median duration of antineoplaston administration was 5 months, and

the average dosage of A10I was 9.22 g/kg/d and of AS2-1 was 0.31 g/kg/d.

 

Responses were assessed by gadolinium-enhanced magnetic resonance

imaging and positron emission tomography. RESULTS: The overall

survival at 2 and 5 years was 39% and 22%, respectively, and maximum

survival was more than 17 years for a patient with anaplastic

astrocytoma and more than 5 years for a patient with glioblastoma.

 

Progression-free survival at 6 months was 39%. Complete response was

achieved in 11%, partial response in 11%, stable disease in 39%, and

progressive disease in 39% of patients.

 

Antineoplastons were tolerated very well with 1 case of grade 4

toxicity (reversible anemia).

 

CONCLUSION: Antineoplastons contributed to more than a 5-year survival

in recurrent diffuse intrinsic glioblastomas and anaplastic

astrocytomas of the brainstem in a small group of patients.

 

 

Subject Headings

Major Subject Heading(s) Minor Subject Heading(s)

PreMedline Identifier: 16484713